<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845839/" ref="ordinalpos=1706&amp;ncbi_uid=5954061&amp;link_uid=PMC3845839" image-link="/pmc/articles/PMC3845839/figure/F4/" class="imagepopup">Fig. 4. Response to heregulin and ErbB3 abundance are key predictors for response to drugs targeting the PI3K/Akt <span class="highlight" style="background-color:">pathway</span>.  From: Profiles of Basal and Stimulated Receptor <span class="highlight" style="background-color:">Signaling</span> Networks Predict Drug Response in Breast Cancer Lines. </a></div><br /><div class="p4l_captionBody"><b>(A)</b> Quality of the predictions for the drugs targeting the PI3K/Akt pathway using their basal and signaling (based on maximal response) profiles. Non-significant predictions (NS) are set to zero. <b>(B)</b> Projection of cell lines according to the pERK response to heregulin and cumulative amounts of ErbB2 and ErbB3 overlaid with the GI50 value to GSK2126458 (red, resistant; blue, sensitive). <b>(C)</b> Quality of the prediction for drugs targeting the PI3K/Akt pathway using a linear model with a single variable or the variables ErbB3 and ErbB2.</div></div>